Methylprednisolone accelerates the resolution of glomerulonephritis by sensitizing mesangial cells to apoptosis

Exp Nephrol. 2001;9(5):317-26. doi: 10.1159/000052627.

Abstract

Glucocorticoid has long been used to treat patients with glomerulonephritis because it ameliorates mesangial cell proliferation and proteinuria, in part by suppressing nuclear factor-kappa B (NF-kappaB) activation, which regulates the transcription of various pro-inflammatory genes. Recent evidence shows that NF-kappaB activation increases the resistance to TNF-alpha-induced apoptosis in mesangial cells. We examined glomerular cell proliferation and apoptosis along with NF-kappaB activation in the Thy-1.1 nephritis model. We also evaluated TNF-alpha-induced apoptosis in cultured mesangial cells. Methylprednisolone treatment ameliorated mesangial hypercellularity in Thy-1.1 nephritis by decreasing proliferating cells and increasing apoptosis in the glomeruli. These effects were associated with suppressed NF-kappaB activation. This in vitro study revealed that treatment with methylprednisolone and TNF-alpha induced cultured mesangial cell apoptosis. These results suggest that methylprednisolone may accelerate the resolution phase of Thy-1.1 nephritis in part by sensitizing mesangial cells to apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis*
  • Cells, Cultured
  • Disease Models, Animal
  • Glomerular Mesangium / drug effects
  • Glomerular Mesangium / pathology*
  • Glomerulonephritis / drug therapy*
  • Glomerulonephritis / pathology
  • Glucocorticoids / therapeutic use
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Male
  • Methylprednisolone / therapeutic use*
  • NF-kappa B / metabolism
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Glucocorticoids
  • NF-kappa B
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Methylprednisolone